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Abstract
Background: To investigate the role of vascular endothelial growth factors (VEGF)-C/D and their
receptor Flt-4 in the lymphatic metastasis of early-stage invasive cervical carcinoma.
Methods: Immunohistochemical (IHC) staining with the antibodies against VEGF-C, VEGF-D, and
Flt-4 was used to examine the expression of them in 97 cases of early-stage cervical carcinoma (Ia-
IIa). Meanwhile, the lymphatic vessel density (LVD) was measured using the antibody against
lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1). We then analyzed the correlation
between Flt-4-positive vessel density (FVD), LVD and clinicopathological features of the tumors.
Results: (1) The positive rates of VEGF-C, VEGF-D, and Flt-4 were 57.7%, 60.8%, and 52.6% in the
cervical tumor samples, respectively. (2) The expression levels of VEGF-C, VEGF-D, and Flt-4 were
significantly correlated with lymphatic metastasis and lymphatic vessel invasion. LVD was
significantly associated with lymph node metastasis and lymphatic vessel invasion. On the other
hand, FVD was strongly associated with clinical staging. (3) The expression levels of VEGF-C and
VEGF-D were significantly correlated with LVD and FVD, while Flt-4 levels showed no correlation
with LVD or FVD.
Conclusion: VEGF-C/D and Flt-4 may play an important role in the process of lymphatic
metastasis of early-stage invasive cervical carcinoma through paracrine and autocrine mechanisms.
Background
Cervical cancer is the most common malignant gyneco-
logical cancer, and lymphatic metastasis is one of the most
important metastatic routes of this cancer. The involve-
ment of the lymphatic node is usually one of the factors
predicting the prognosis. Along with the development of
specific markers of lymphatic endothelium [1] and the
improvement of isolation techniques for lymphatic
endothelial cells [2], the role of tumor lymphangiogenesis
in the metastasis of early-stage cervical carcinoma is grad-
ually becoming a research focus. Even so, the mechanism
of the tumor lymphatic metastasis is still largely unknown
and there is a great deal of debate over various aspects of
research in the field. In this study, we employed immuno-
histochemical (IHC) staining to detect the expression of
VEGF-C, VEGF-D, and Flt-4 in early-stage cervical carci-
noma (Ia-IIa). The lymphatic vessel endothelial hyaluro-
nan receptor-1 (LYVE-1), the labeled lymphatic vessel
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were also measured and analyzed relative to the clinico-
pathological features of the tumors. Our study explored
the roles of VEGF-C, VEGF-D, and FLt-4 in the lymphatic
metastasis of early-stage cervical cancer.
Materials and methods
Patients and tissue samples
Patients with cervical carcinoma who were treated
between September 2007 and February 2009 were
enrolled in this study (n = 97). The tissue samples were
obtained at the time of surgery from the Department of
Gynecology, Qilu Hospital, Shandong University. Sam-
ples and clinical data were collected after informed con-
sent was obtained. Tissues were fixed with 4%
paraformaldehyde and paraffin-embedded for further
analysis. The pathological examination verified that no
radio- or chemotherapy was received before surgery. Our
study was approved by the Ethics Committee of Shandong
University. All patients with early-stage invasive cervical
cancer were staged according to the 2000 International
Federation of Gynecology and Obstetrics (FIGO) staging
system. Sixteen of the patients had cervical cancer classi-
fied as FIGO stage Ia, 33 as FIGO stage Ib, and 48 as FIGO
stage IIa. Based on the analysis of cellular differentiation,
21 cases were HG1, 31 were HG2, and 45 were HG3. Of all
the cases, 81 were squamous cell carcinomas and 16 were
adeno-carcinomas. All the patients received pelvic or para-
abdominal aortic lymphadenectomy and in total 2376
lymph nodes were dissected (mean 24.5, median 24.0). A
histological review confirmed that 30 cases (30.9%)
showed lymph node metastasis and 75 lymph nodes were
metastasis positive (mean 2.5, median 2). The age of the
patients varied from 26 to 70, with a median value of 42.
Of all the patients, 68 were premenopausal and 29 were
postmenopausal. The standard for lymphatic vessel inva-
sion was the detection of cancer cells in the cavity of the
lymphatic vessel by light microscopy. By this standard, 39
cases showed lymphatic vessel invasion and 58 were neg-
ative. All tissue specimens and slides were examined by
experienced pathologists.
Reagents
The reagents used in this study included: rabbit anti-
human VEGF-C polyclonal antibody from Zhongshan
Goldenbridge Biotech (Beijing, China; catalog no. ZA-
0266, 1:50 dilution); rabbit anti-human VEGF-D polyclo-
nal antibody from Boster Inc. (Wuhan, Hubei, China; cat-
alog no. BA1461, 1:100 dilution); rabbit anti-human Flt-
4 polyclonal antibody from Abcam (Cambridge, MA,
USA; catalog no. ab27278, 1:200 dilution); rabbit anti-
human LYVE-1 polyclonal antibody from Abcam (Cam-
bridge, MA, USA; catalog no. ab36993, 1:80 dilution);
and an immunohistochemistry SP kit from Jingmei Inc.
(Shanghai, China; catalog no. LHK612).
Immunohistochemistry
Immunohistochemistry (IHC) was conducted using the
immunohistochemistry SP kit from Jingmei Inc. accord-
ing to the manufacturer's instructions. Briefly, serial sec-
tion slides of 5 mm were obtained from the paraffin-
embedded specimens. After regular de-paraffin and re-
hydration, the slides were placed in an antigen retrieval
solution (pH 6.0) and heated in a microwave oven for 10
min at 95°C. Next, the slides were incubated in a 3%
hydrogen peroxide-methanol solution for 10 min to
remove endogenous peroxidase. IHC staining was per-
formed as follows: nonspecific binding was blocked with
10% goat serum; the slide was incubated for 1 h with pri-
mary antibodies, followed by incubation for 30 min with
a biotin-labeled secondary antibody; and subsequently
the slide was incubated for 30 min with horseradish per-
oxidase-labeled streptavidin. Color was developed using
DAB, and the slide was counterstained with hematoxylin.
Finally, the slides were mounted and coverslipped with
resinene. Negative control slides were stained with PBS
instead of the primary antibodies. Breast cancer slides
were used as a positive control.
VEGF-C, VEGF-D, and Flt-4 positive cells showed brown-
yellow particles in their cytoplasm. According to the
method described by Jüttner et al.[3], the samples were
classified as follows: - (no positive cell), + (0–5% positive
cell), ++ (5–50% positive cell), +++ (>50% positive cell).
Among these, ++ and +++ samples were determined to
have a positive expression. LVD and FVD were determined
according to the methods previously described by Wei-
dner et al. [4]. Briefly, the slides were scanned on a low-
power microscope and areas with the highest positively
stained vessel density, called hot spots, were identified.
The number of positively stained lymphatic vessels in five
high-power fields in the selected areas was counted. LVD
and FVD were determined as the mean value of vessel
counts.
Statistical Analysis
All statistical calculations were performed using SPSS (ver-
sion 13.0, Chicago, IL USA). LVDs and FVDs were
The expression of VEGF-C (A), VEGF-D (B), and Flt-4 (C) in cervical carc noma tissuesFigure 1
The expression of VEGF-C (A), VEGF-D (B), and Flt-
4 (C) in cervical carcinoma tissues. A. IHC detection of 
VEGF-C ( ) ×400; B. IHC detection of VEGF-D ( ) ×400; 
and C. IHC detection of Flt-4 ( ) ×400.
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included the t-test, the one-way ANOVA test, and the Chi-
square test. Differences were considered to be statistically
significant when P < 0.05.
Results
Expression of VEGF-C, VEGF-D and Flt-4 in cervical cancer 
tissue
The IHC signals of VEGF-C, VEGF-D, and their receptor
Flt-4 were mostly localized in the cytoplasm of the cancer
cell in the examined cervical carcinoma samples and the
positively stained cells showed a brown-yellow color in
the cytoplasm. The positive rates were 57.7% (56 out of
97) for VEGF-C, 60.8% (59 out of 97) for VEGF-D, and
52.6% (51 out of 97) for Flt-4 (Figure 1A).
Next, we analyzed the correlation between the VEGF-C,
VEGF-D, and Flt-4 signals and the pathological features.
The results from statistical analyses showed that the
expression of both VEGF-C and VEGF-D were positively
correlated with lymph node metastasis and lymphatic ves-
sel invasion, but expression was not associated with men-
opause, tumor size, stromal invasion, FIGO stage,
histological grade, or histological types. Similarly, Flt-4
expression was only associated with lymph node metasta-
Table 1: Correlation of expression of VEGF-C, VEGF-D, and Flt-4 in cervical cancer tissues with clinicopathological parameters
Variables n VEGF-C VEGF-D Flt-4
(+) (-) P (+) (-) P (+) (-) P
Catamenia
Premenopause 68 37 31 NS 42 26 NS 33 35 NS
Postmenopause 29 19 10 17 12 18 11
Tumor size (cm)
£4 61 36 25 NS 35 26 NS 30 31 NS
>4 36 20 16 24 12 21 15
Stromal invasion
£2/3 40 22 18 NS 27 13 NS 24 16 NS
>2/3 57 34 23 32 25 27 30
FIGO stage
I a 16 10 6 NS 7 9 NS 9 7
I b 33 18 15 22 11 18 15
II a 48 28 20 30 18 24 24
Histological grade NS
HG1 21 9 12 NS 12 9 NS 10 11
HG2 31 18 13 20 11 15 16
HG3 45 29 16 27 18 26 19
Lymph node metastasis
Negative 67 33 34 0.012 35 32 0.010 30 37 0.022
Positive 30 23 7 24 6 21 9
LVI
Negative 39 16 23 0.006 18 21 0.015 14 25 0.007
Positive 58 40 18 41 17 37 21
Histological cell type
SCC 81 46 35 NS 50 31 NS 43 38 NS
ADE 16 10 6 9 7 8 8
Abbreviations: HG, histological grade; LVI, lymphatic vessel invasion; SCC, squamous cell carcinoma; and ADE, adenocarcinoma. P, chi-square test.
Morphological features of LYVE-1 positive lymphatic vessels and Flt-4 positive vessels in cervical cancer tissuesFigure 2
Morphological features of LYVE-1 positive lymphatic 
vessels and Flt-4 positive vessels in cervical cancer 
tissues. A. The LYVE-1 positive lymphatic vessels ( ) were 
clearly different from blood vessels ( ) ×200; B. The LYVE-1 
positive lymphatic vessels ( ) were mainly distributed in the 
paratumor stromal tissue ( ) ×400; C. Some LYVE-1 posi-
tive lymphatic vessels contained invaded tumor cells ( ) 
×400; D. Some Flt-4 positive vessels were similar to blood 
vessels in their morphology ( ), and others were similar to 
lymphatic vessels ( ) ×400; E. The Flt-4 positive vessels ( ) 
were mainly distributed in the paratumor stromal tissue ( ) 
×400; and F. Some Flt-4 positive vessels contained invaded 
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factors analyzed (Table 1).
Lymphatic vessel density and Flt-4 positive vessel density
Analysis under a light microscope showed that the LYVE-
1 positive vessels were composed of a single layer of cells
with a large nucleus extruding towards the lumen face.
The basal and lumen faces were both stained in a brown-
yellow color, which was clearly different from blood ves-
sels (Figure 2A). These lymphatic vessels were mostly dis-
tributed in the stromal tissue surrounding the tumor
(Figure 2B), and tumor cells were observed in some LYVE-
1 positive lymphatic vessels (Figure 2C). Under the light
microscope, some of the Flt-4 positive vessels showed
blood vessel morphology and the others showed lym-
phatic vessel morphology (Figure 2D). Most of the Flt-4
positive vessels were distributed in the stromal tissue sur-
rounding the tumors (Figure 2E). Some of the Flt-4 posi-
tive lymphatic vessels contained tumor cells which were
also Flt-4 positive (Figure 2F).
We also analyzed the LVD and FVD. LVD was positively
correlated with lymph node metastasis and lymphatic ves-
sel invasion of the tumor, but not with menopause, tumor
size, depth of stromal invasion, FIGO stage, histological
grade, or histological type. FVD was positively associated
with FIGO stage, but not with the other pathological fea-
tures (Table 2).
We also cross-analyzed the correlation of expression levels
of VEGF-C, VEGF-D, and Flt-4 with LVD and FVD. We
found that the expression of VEGF-C and VEGF-D was cor-
related with LVD and FVD, but the expression of Flt-4 was
not associated with LVD and FVD (Table 3).
Table 3: Association of expression of VEGF-C, VEGF-D, and Flt-4 
with LVD and FVD in cervical carcinoma
n LVD P FVD P
VEGF-C (+) 56 18.10 ± 0.85 0.026 27.05 ± 0.86 0.020
(-) 41 17.87 ± 1.02 26.60 ± 1.00
VEGF-D (+) 59 17.88 ± 0.94 0.046 26.82 ± 1.28 0.022
(-) 38 17.49 ± 0.91 26.18 ± 1.38
Flt-4 (+) 51 17.15 ± 1.01 NS 25.63 ± 1.66 NS
(-) 46 16.77 ± 1.32 26.06 ± 1.47
Abbreviations: LVD, lymphatic vessels density; and FVD, Flt-4-positive 
vessel density. P, chi-square test.
Table 2: Association of LVD and FVD with clinical and pathological parameters
Variables n LVD FVD
mean ± SD P mean ± SD P
Catamenia
Premenopause 68 17.00 ± 1.63 NS 25.97 ± 1.48 NS
Postmenopause 29 16.33 ± 1.44 25.41 ± 1.83
Tumor size (cm)
£4 61 16.66 ± 1.26 NS 26.32 ± 1.92 NS
>4 36 17.06 ± 1.22 26.97 ± 1.84
Stromal invasion
£2/3 40 16.29 ± 0.86 NS 25.82 ± 1.66 NS
>2/3 57 16.69 ± 1.23 26.02 ± 1.70
FIGO stage
a 16 16.43 ± 1.40 NS* 25.09 ± 1.49 0.032*
b 33 17.07 ± 1.49 25.21 ± 1.62
a 48 17.10 ± 1.52 26.10 ± 1.85
Histological grade
HG1 21 16.86 ± 1.57 NS* 25.43 ± 1.98 NS*
HG2 31 17.15 ± 1.14 26.08 ± 1.75
HG3 45 17.24 ± 1.37 25.76 ± 1.37
Lymph node metastasis
Negative 67 17.15 ± 1.49 0.025 25.70 ± 1.84 NS
Positive 30 17.93 ± 1.70 26.33 ± 1.82
LVI
Negative 39 16.49 ± 1.46 0.001 25.97 ± 1.66 NS
Positive 58 17.66 ± 1.82 26.50 ± 1.74
Histological cell type
SCC 81 16.76 ± 1.62 NS 25.78 ± 1.64 NS
ADE 16 17.25 ± 1.26 26.00 ± 1.15
Abbreviations: HG, histological grade; LVI, lymphatic vessel invasion; SCC, squamous cell carcinoma; ADE, adenocarcinoma, LVD, lymphatic vessels 
density; and FVD, Flt-4-positive vessel density. P, t-test; P*, one-way ANOVA test.Page 4 of 6
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Within research exploring the mechanisms of tumor
metastasis, there are more and more studies examining
the relationship between tumor lymphangiogenesis and
tumor metastasis. The important role of lymphatic vessels
in tumor metastasis, and especially solid tumor metasta-
sis, has been recognized gradually. Clinicopathological
research has demonstrated that the earliest path for solid
tumor metastasis is regional spreading to the lymph
nodes through lymphatic vessels. The regulatory mecha-
nism for lymphangiogenesis in tumors is complicated and
there are multiple factors involved. Among them, VEGF-
C, VEGF-D, and Flt-4 were thought to be the major regu-
latory factors for tumor lymphangiogenesis, and likely
play an important role in the lymphatic tumor metastasis.
Animal tumor models with overexpression of VEGF-C or
VEGF-D have shown that the lymphatic endothelial cells
proliferated quickly in tumor tissues, LVD increased sig-
nificantly, and lymph node metastasis was also enhanced.
Jeltsch et al. [5] reported that high-expression of VEGF-C
in a K14-VEGF-C transgenic mice model promoted lym-
phatic endothelial cell proliferation and enlargement of
lymph vessel cavity in the dermis of mice. Von Marschall
et al. [6] transplanted human pancreatic duct cancer cells
that overexpressed VEGF-D into nude mice and detected
LYVE-1 positive lymphatic vessels. They found that VEGF-
D significantly induced the lymphangiogenesis, increased
LVD in the tumor tissues, and was closely related to the
significantly increased lymphatic vessel invasion and
lymph node metastasis. In our study, we showed that
VEGF-C, VEGF-D, and Flt-4 were significantly correlated
with lymph node metastasis and lymphatic vessel inva-
sion. Meanwhile, we used a polyclonal LYVE-1 antibody
to label lymphatic vessels. Since the measurement of lym-
phatic vessel density can be quite subjective, a strategy was
applied in which the lymphatic vessel density was meas-
ured by two expert pathologists, who were blinded for
clinical data. LVD counting demonstrated that LVD was
associated with lymph node metastasis and lymphatic
vessel invasion and was closely related to levels of VEGF-
C and VEGF-D, which is consistent with previous clinical
studies [7-9]. The underlying mechanism may be secre-
tion of VEGF-C and VEGF-D by tumor cells, which then
function through the receptor tyrosine kinase Flt-4 in lym-
phatic endothelial cells in a paracrine manner and pro-
mote endothelial proliferation, differentiation and cavity
formation. These newly generated lymphatic vessels in
tumor tissues are structurally similar to the physiological
lymphatic vessels, but occur in large numbers and in thin
walls. These features provide more paths for tumor cell
infiltration and facilitate tumor metastasis.
The mechanism of tumor lymphangiogenesis is compli-
cated and involves an interaction between tumor cells and
lymphatic endothelial cells. It has been shown that
increased lymphatic vessels in tumor not only provide
paths for tumor cell metastasis, but also release proteases
under the stimulation of VEGF-C and promote basal
membrane infiltration of tumor cells [10]. On the other
hand, VEGF-C also changed the adherent features and
expression of surface chemo-attractants and receptors,
affected the process by which tumor cells enter lymphatic
vessels and therefore actively promote the tumor lym-
phatic metastasis [11].
Although increased LVD provides more metastatic pathways
and plays an important role in tumor lymphatic metastasis,
the process of tumor lymphatic metastasis is complicated
and has multiple steps, including tumor cell migration, deg-
radation of extracellular matrix, and relocation. Migration
and invasion of tumor cells are prerequisites for tumor
metastasis and infiltration. As the receptor for VEGF-C and
VEGF-D, Flt-4 is expressed in not only the lymphatic
endothelial cells, but also in the liver and spleen blood sinus,
during injury repair, and in newly generated tumor blood
vessel endothelium. Recent studies have shown that Flt-4
was also expressed in many types of tumor cells [12,13] and
played an important role in tumor lymphatic metastasis and
tumor progression by promoting tumor cell proliferation,
growth, and migration [14].
Su et al. [15] used in vitro migration and invasion meth-
ods and found that some tumor cells with a strong inva-
sion ability, such as cervical carcinoma cell SiHa, had not
only a high expression level of VEGF-C, but also a high
level of Flt-4. Human recombinant VEGF-C (Cys 156 Ser)
protein could promote the migration and invasion of
tumor cells. Application of recombinant Flt-4/Fc blocked
signaling of VEGF-C and also significantly decreased
tumor migration and invasion. This suggested that Flt-4/
Fc enhances lymphangiogenesis by affecting paracrine sig-
naling, and that VEGF-C, VEGF-D and Flt-4 might also
have an autocrine function in promoting tumor cell
migration and invasion, which could eventually lead to
tumor lymphatic metastasis. Van et al. [16] found that in
the transition from localized cervical epithelial neoplasia
to metastatic cervical carcinoma, the expression of VEGF-
C, VEGF-D, and Flt-4 increased gradually. Therefore, it
was speculated that VEGF-C, VEGF-D and Flt-4 could be
involved in the process of phenotypic transition to lym-
phangiogenesis and could facilitate lymphatic metastasis
in the early stages of cervical cancer. In addition, Masood
et al. [17] found that VEGF-C and VEGFR-3 activation pro-
moted the growth of malignant pleural endotheliomas.
Consistently, the application of antisense oligos against
VEGF-C, recombinant VEGFR-3/Fc, or VEGFR-3 antibody
to inhibit VEGF-C/VEGFR-3 signaling led to a significantly
lower survival of malignant pleural endotheliomas cells.
In the current study, we found that in cervical carcinoma,
Flt-4 was expressed not only in blood vessel and lym-
phatic vessel endothelial cells, but also in tumor cells, and
that the level of Flt-4 was positively correlated with lymphPage 5 of 6
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inconsistent with the results from a previous study by Jüt-
tner et al. [3]. One possible reason for this inconsistency
is that there are multiple receptors of VEGF-C and VEGF-
D and their expression is heterogeneous in different
tumor cells. Except for Flt-4, VEGFR-2, NRP-1 and NRP-2
can all function as receptors for VEGF-C and VEGF-D [18].
Therefore, the roles of VEGF-C, VEGF-D, and Flt-4 in the
progress of tumors are omnifarious and the underlying
mechanisms of these growth factors need to be further
studied.
Our research showed that the specificity of Flt-4 as a lym-
phatic vessel marker was not high. Some of the Flt-4 pos-
itive vessels were morphological blood vessels and other
vessels were lymphatic vessels. We found that FVD was
positively associated with the FIGO stage of cervical can-
cer, but was not related to the other clinicopathological
features including histological grade, lymph node metas-
tasis, or lymphatic vessel infiltration. In addition, we
found that FVD was correlated with the expression of
VEGF-C and VEGF-D. This is inconsistent with Yasuoka et
al. [19]. The VEGF receptor tyrosine kinase family
includes VEGFR-1, VEGFR-2, and VEGFR-3. VEGF-1 and
VEGF-2 are primarily expressed in blood vessel endothe-
lial cells and are involved in tumor angiogenesis. Since Flt-
4 is expressed in the endothelial cells of blood vessels and
lymphatic vessels, VEGF-C, VEGF-D, and Flt-4 may also
play important roles in tumor angiogenesis [20].
In summary, our results indicated that VEGF-C, VEGF-D,
and Flt-4 may promote tumor lymphangiogenesis and
may provide a spreading route for tumor metastasis
through a paracrine mechanism. On the other hand, they
may function in an autocrine manner to enhance tumor
cell migration and invasion and may therefore play an
important role in the lymphatic vessel metastasis of early-
stage cervical carcinoma.
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